⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 10, 2024AIDSOpen Access

Negative impact of a health insurer-mandated de-simplification from a single-tablet regimen to a two-tablet regimen

Piter Oosterhof Matthijs van Luin Kees Brinkman David M. Burger

View Full Paper

Ask AI

Bookmark

Share

Abstract

Antiretroviral therapy (ART) accounts for a considerable proportion of HIV care expenses. In June 2021, a Dutch healthcare insurer implemented a mandatory policy to de-simplify branded RPV/TDF/FTC (Eviplera) into a two-tablet regimen containing rilpivirine (Edurant) and generic TDF/FTC as part of cost-saving measures. The objectives of this study were to evaluate the acceptance of this policy, the trends in ART dispensation, and cost developments.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Oosterhof et al. (2024) studied this question.

synapsesocial.com/papers/68e6fb85b6db643587675607 https://doi.org/10.1097/qad.0000000000003905

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1De‐simplifying antiretroviral therapy from a single‐tablet to a two‐tablet regimen: Acceptance, patient‐reported outcomes, and cost savings in a multicentre study2024 · 5 citations
2Impact of Generic Antiretroviral Drugs Introduction on Pharmaceutical Expenditure Patterns in the Netherlands: A Six-Year Retrospective Database Analysis from 2016 to 20222024
3Uptake of drug-reduced antiretroviral strategies and impact on costs over 2015–22: experience from an HIV clinic in Paris, France2025 · 2 citations
4First-line antiretroviral therapy initiation for newly diagnosed people with HIV in the Netherlands: A retrospective analysis from 2016 to 20202024
52SPD-004 Budgetary impact of the introduction of cabotegravir plus rilpivirine long-acting in a third-level hospital2024